Krasmutant genetically engineered mouse models of human cancers are genomically heterogeneous
©Adam Gault/OJO Images/Getty
Mice genetically engineered to have a cancer-causing mutation grow tumours with as much variability as human tumours, affirming their value in discovering and testing therapies.
The KRAS gene is mutated in many human cancers,
such as bowel and lung, and treatments for these tumours are lacking. Mice
genetically engineered to carry KRAS mutations
are often used as models to study these cancers but their tumours have not been
well-characterized. Researchers at Roche analysed gene expression and the
accumulation of mutations in these mouse models and compared them with human
team found significant genetic variation both within and between tumours in the
mice. The level of variation was similar to that in human tumours, and although
the types of mutations differed, many of the same genes were mutated in the
mouse and human tumours. The thorough understanding of the genetic diversity of
these mouse models will improve our ability to develop and test therapies.
- PNAS 114, E10947-E10955 (2017). doi: 10.1073/pnas.1708391114
|Genentech, Inc., United States of America (USA)||1.00|